Beranda › Limfoma Non-Hodgkin › Washington › Seattle
Uji klinis Limfoma Non-Hodgkin di Seattle, WA
16 studi untuk Limfoma Non-Hodgkin mencari peserta di lokasi sekitar Seattle (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Menerima pesertaFase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Menerima pesertaFase 2
- Swedish Cancer Institute, Seattle
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Menerima pesertaFase 1
- Swedish Cancer Institute (SCI), Seattle
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Menerima pesertaFase 1
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Menerima pesertaFase 1/2
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Menerima pesertaFase 1
- Fred Hutch Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Menerima pesertaFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
DALY II USA/ MB-CART2019.1 for DLBCL
Menerima pesertaFase 2
- Fred Hutchinson Cancer Center, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Menerima pesertaStudi observasional
- Fred Hutchinson Cancer Research Center, Seattle
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Menerima pesertaFase 1/2
- University of Washington Medical Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Menerima pesertaFase 4
- Swedish Cancer Institute, Seattle
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Menerima pesertaFase 4
- Swedish Cancer Institute, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
Menerima pesertaFase 1
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Menerima pesertaFase 1
- Swedish Cancer Institute, Seattle
Uji klinis Limfoma Non-Hodgkin di kota lain
- New York City, NY31 studi
- Houston, TX31 studi
- Boston, MA26 studi
- Nashville, TN21 studi
- Philadelphia, PA20 studi
- Baldwin Park, CA19 studi
- Washington, DC18 studi
- Chicago, IL18 studi
- Atlanta, GA18 studi
- Milwaukee, WI18 studi
- Columbus, OH18 studi
- Dallas, TX17 studi
Studi lain di Seattle
- Kanker Paru Non-Sel Kecil53 studi
- Kanker (semua jenis)49 studi
- Kanker Prostat42 studi
- Leukemia Mieloid Akut41 studi
- Kanker Payudara39 studi
- Kanker Metastatik39 studi
- Kanker Kolorektal34 studi
- Kanker Paru33 studi
- Kanker Ovarium30 studi
- Mieloma Multipel22 studi
- Kanker Kandung Kemih21 studi
- Sindrom Mielodisplastik21 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.